This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2021 Jul 27;326(4):359-360.

doi: 10.1001/jama.2021.8154.

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia-Reply

Franco Locatelli¹, Gerhard Zugmaier², Arend von Stackelberg³

Affiliations

Affiliations

¹ IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.
² Amgen Research, Munich, Germany.
³ Charité-Universitätsmedizin Berlin, Berlin, Germany.

PMID: 34313692
DOI: 10.1001/jama.2021.8154

Comment

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia-Reply

Franco Locatelli et al. JAMA. 2021.

. 2021 Jul 27;326(4):359-360.

doi: 10.1001/jama.2021.8154.

Authors

Franco Locatelli¹, Gerhard Zugmaier², Arend von Stackelberg³

Affiliations

¹ IRCCS Ospedale Pediatrico Bambino Gesù, Sapienza University of Rome, Rome, Italy.
² Amgen Research, Munich, Germany.
³ Charité-Universitätsmedizin Berlin, Berlin, Germany.

PMID: 34313692
DOI: 10.1001/jama.2021.8154

No abstract available

PubMed Disclaimer

Comment on

Blinatumomab vs Chemotherapy Among Children With Relapsed Acute Lymphoblastic Leukemia.
Shibusawa M, Kidoguchi K, Tanimoto T. Shibusawa M, et al. JAMA. 2021 Jul 27;326(4):359. doi: 10.1001/jama.2021.8151. JAMA. 2021. PMID: 34313694 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems